Tags

Type your tag names separated by a space and hit enter

[The endocannabinoid system and treatment of obesity].
Tidsskr Nor Laegeforen. 2008 Feb 28; 128(5):570-1.TN

Abstract

Rimonabant is a novel drug for treatment of obesity. Four randomised studies have shown a significant effect of 20 mg rimonabant on bodyweight and other cardiovascular risk factors. The weight loss is modest, approximately 5 %, and the patients regain their baseline weight within 9 months after withdrawal. There is no evidence that rimonabant reduces morbidity or mortality, and no comparative studies with orlistat or sibutramine have been performed. Long-term effects of blocking the endocannabinoid system are not known. Side effects are nausea, depressive symptoms, anxiety and dizziness. There are reports on increased suicidality, and rimonabant is contraindicated in depressed patients.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

nor

PubMed ID

18311201

Citation

Aronsen, Lena. "[The Endocannabinoid System and Treatment of Obesity]." Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, vol. 128, no. 5, 2008, pp. 570-1.
Aronsen L. [The endocannabinoid system and treatment of obesity]. Tidsskr Nor Laegeforen. 2008;128(5):570-1.
Aronsen, L. (2008). [The endocannabinoid system and treatment of obesity]. Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, 128(5), 570-1.
Aronsen L. [The Endocannabinoid System and Treatment of Obesity]. Tidsskr Nor Laegeforen. 2008 Feb 28;128(5):570-1. PubMed PMID: 18311201.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The endocannabinoid system and treatment of obesity]. A1 - Aronsen,Lena, PY - 2008/3/4/pubmed PY - 2008/3/14/medline PY - 2008/3/4/entrez SP - 570 EP - 1 JF - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke JO - Tidsskr Nor Laegeforen VL - 128 IS - 5 N2 - Rimonabant is a novel drug for treatment of obesity. Four randomised studies have shown a significant effect of 20 mg rimonabant on bodyweight and other cardiovascular risk factors. The weight loss is modest, approximately 5 %, and the patients regain their baseline weight within 9 months after withdrawal. There is no evidence that rimonabant reduces morbidity or mortality, and no comparative studies with orlistat or sibutramine have been performed. Long-term effects of blocking the endocannabinoid system are not known. Side effects are nausea, depressive symptoms, anxiety and dizziness. There are reports on increased suicidality, and rimonabant is contraindicated in depressed patients. SN - 0807-7096 UR - https://www.unboundmedicine.com/medline/citation/18311201/[The_endocannabinoid_system_and_treatment_of_obesity]_ L2 - http://tidsskriftet.no/article/1661310 DB - PRIME DP - Unbound Medicine ER -